HOME >> MEDICINE >> NEWS
Statins, beta-blockers lessen heart attack risk, says Stanford-Kaiser study

For patients with undiagnosed heart disease, taking medications known as statins and beta-blockers may mean the difference between suffering a heart attack as a first symptom versus experiencing mild chest pain.

New research from the Stanford University School of Medicine suggests that these preventive drugs can steer patients away from having a heart attack toward the less serious symptom of mild chest pain that occurs only with exercise (angina) even if they don't stop the build-up of cholesterol in a patient's arteries. The study, to be published in the Feb. 21 issue of the Annals of Internal Medicine, was conducted with investigators at Kaiser Permanente Division of Research in Oakland and the University of California-San Francisco.

"That's the scary thing about heart disease," said senior author Mark Hlatky, MD, professor of health research and policy and of cardiovascular medicine at Stanford. "You can be fine one minute and dead the next. You can put up with a little chest pain every once in a while if you know you're not about to die from it."

Researchers for the study wanted to know how doctors could help reduce a patient's risk of having a heart attack as a first symptom even if medications for high blood pressure or high cholesterol were unsuccessful in stopping the onset of heart disease. Statins are typically prescribed to reduce cholesterol, one of the warning signs for heart disease. Beta-blockers are given to patients with high blood pressure, another warning sign for heart disease.

"While doctors try to prevent coronary disease by treating high blood pressure and high cholesterol, it's not 100 percent effective," Hlatky said. "If there are warning symptoms like angina with exercise, there is enough time to see a doctor and get started on effective treatments that reduce risk. Having a heart attack causes permanent damage, even if it doesn't kill you."

Researchers evaluated 1,400 patients enrolled within Kaiser
'"/>

Contact: Tracie White
tracie.white@stanford.edu
650-723-7628
Stanford University Medical Center
20-Feb-2006


Page: 1 2

Related medicine news :

1. Experimental gene therapy abolishes arthritis pain and lessens joint damage
2. Warm blanket lessens chances of false-positives in cancer scans
3. Antidepressants lessen risk of heart attack, Stanford researcher says
4. Patients favorite music during surgery lessens need for sedative
5. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
6. Drug for cluster headaches may cause heart problems
7. Reductive stress linked to heart disease
8. Novel candidate biomarker for heart failure also strongly predicts risk of death
9. Many heart attack patients still not getting emergency clot-busting treatment
10. New heart disease risk score will help minimize health inequalities
11. Metabolic syndrome points to heart health

Post Your Comments:
(Date:1/23/2015)... AZ (PRWEB) January 23, 2015 Hastings and ... injury matters, reports a record number of legal representation client ... speaking, there has been a steady rise in the number ... work and at home throughout the Valley. With that said, ... accident be reviewed by an experienced law firm. Hastings and ...
(Date:1/22/2015)... 22, 2015 The City of West Hollywood hosted ... to commemorate the 42nd anniversary of the Supreme Court decision Roe ... been 42 years since the Roe vs. Wade decision and the ... present as ever,” said City of West Hollywood Councilmember Abbe Land. ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
(Date:1/23/2015)... 23, 2015  MedScope ( www.medscope.org ), the leading provider ... 2015 Connected World magazine Connected World Award ... that can be used anywhere, anytime. The nomination was ... In nominating MedScope, Landon Garner , Director ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: